Tocagen Inc (NASDAQ:TOCA) has earned a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Analysts have set a 12-month consensus price objective of $23.67 for the company, according to Zacks. Zacks has also given Tocagen an industry rank of 104 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research downgraded Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th.
Tocagen (NASDAQ:TOCA) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.02). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. research analysts anticipate that Tocagen will post -2.88 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of TOCA. TD Asset Management Inc. acquired a new position in shares of Tocagen during the second quarter worth about $158,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Tocagen during the second quarter worth about $165,000. Alps Advisors Inc. acquired a new position in shares of Tocagen during the second quarter worth about $215,000. Bank of New York Mellon Corp acquired a new position in shares of Tocagen during the second quarter worth about $281,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Tocagen during the second quarter worth about $837,000. Institutional investors own 36.22% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/05/tocagen-inc-toca-given-23-67-consensus-target-price-by-analysts.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Tocagen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tocagen Inc and related companies.